CEO Johan Spoor was paid $2,404,692 in fiscal year 2025, ↓ down 55.2% from fiscal year 2024, the 6th percentile of its disclosed peer group (SEC filing 0001193125-26-159005 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$2,404,692 ↓ Johan Spoor total, FY2025 | 6th CEO pay percentile vs peers | — CEO-to-median pay ratio | 73.68% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
CATX's next annual pay disclosure, estimated April 16, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Johan Spoor | $680,000 | $0 | $0 | $1,302,692 | $408,000 | $0 | $14,000 | $2,404,692 |
| Chief Executive Officer, Director | ||||||||
| Juan Graham | 334,734 | 80,000 | 0 | 1,159,779 | 0 | 0 | 660,417 | 2,234,930 |
| Former Chief Financial Officer | ||||||||
| Joel Sendek | 163,014 | 0 | 0 | 1,750,838 | 65,200 | 0 | 7,500 | 1,986,552 |
| Chief Financial Officer | ||||||||
| Markus Puhlmann | 516,700 | 0 | 0 | 330,683 | 206,700 | 0 | 14,000 | 1,068,083 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Johan Spoor | $2,404,692 | $5,371,889 | $1,458,996 | ↓ −2,967,197 |
| Juan Graham | 2,234,930 | — | — | — |
| Joel Sendek | 1,986,552 | — | — | — |
| Markus Puhlmann | 1,068,083 | 2,029,343 | 900,093 | ↓ −961,260 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Perspective Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper CATX reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses CATX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CATX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Joel Sendek | CFO | $1,986,552 |
| Johan Spoor | CEO | $2,404,692 |
| Juan Graham | CFO | $2,234,930 |
| Markus Puhlmann | Chief Medical Officer | $1,068,083 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Frank Morich, M.D., Ph.D | Independent Director | $174,397 |
| Heidi Henson | Independent Director | $174,397 |
| Lori A. Woods | Chair of the Board | $189,397 |
| Maya Martinez-Davis | Independent Director | $227,032 |
| Robert Froman Williamson III | Independent Director | $174,397 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Lantheus Alpha Therapy, LLC | Greater-than-10% holder | 2026-08-31 | D | 78,145 | $3 | $245,610 | Common | Form 4 ↗ |
| Lantheus Holdings, Inc. | Greater-than-10% holder | 2026-08-31 | D | 78,145 | 3 | 245,610 | Common | Form 4 ↗ |
| Lantheus Holdings, Inc. | Greater-than-10% holder | 2026-09-01 | D | 35,769 | 3 | 111,574 | Common | Form 4 ↗ |
| Lantheus Alpha Therapy, LLC | Greater-than-10% holder | 2026-09-01 | D | 35,769 | 3 | 111,574 | Common | Form 4 ↗ |
| Lantheus Alpha Therapy, LLC | Greater-than-10% holder | 2026-09-02 | D | 42,129 | 3 | 131,219 | Common | Form 4 ↗ |
| Lantheus Alpha Therapy, LLC | Greater-than-10% holder | 2026-09-03 | D | 80,783 | 3 | 250,896 | Common | Form 4 ↗ |
| Lantheus Alpha Therapy, LLC | Greater-than-10% holder | 2026-09-04 | D | 167,149 | 3 | 526,051 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Johan Spoor | Option | — | — | — | — | — | $1,302,692 |
| Juan Graham | Option | — | — | — | — | — | 1,159,779 |
| Markus Puhlmann | Option | — | — | — | — | — | 330,683 |
| Joel Sendek | Option | — | — | — | — | — | 1,750,838 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Johan Spoor | $0 | $0 | $1,302,692 | 0.0% |
| Juan Graham | 0 | 0 | 1,159,779 | 0.0% |
| Markus Puhlmann | 0 | 0 | 330,683 | 0.0% |
| Joel Sendek | 0 | 0 | 1,750,838 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Johan Spoor | Option | 83,471 | 2.4 | — |
| Joel Sendek | Option | 600,000 | 3.54 | — |
| Johan Spoor | Option | 528,126 | 2.46 | — |
| Markus Puhlmann | Option | 134,063 | 2.46 | — |
| Markus Puhlmann | Option | 93,750 | 10.65 | — |
| Markus Puhlmann | Option | 36,940 | 2.4 | — |
| Johan Spoor | Option | 312,500 | 10.65 | — |
The Company's compensation policies and philosophies are designed to align compensation with business objectives and the interests of stockholders, while also enabling the Company to attract, motivate and retain individuals who contribute to its long-term success.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-05-28 | 38,730,185 | 13,686,122 | 151,728 | 73.68% | Passed |
| 2022 | 2022-12-13 | 53,042,425 | 12,745,783 | 1,819,202 | 80.63% | Passed |
| 2019 | 2019-12-10 | 10,152,456 | 9,374,808 | 199,914 | 51.99% | Passed |
| 2016 | 2016-12-14 | 7,055,009 | 2,401,194 | 518,867 | 70.73% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-05-28 | 73.68%a |
| 2022 | 2022-12-13 | 80.63%b |
| 2019 | 2019-12-10 | 51.99%c |
a. Approved under the standard stated in the filing — “Proposal 3 (the Say on Pay Proposal). The vote required to approve Proposal 3 is governed by Delaware law and the Company's bylaws and is the affirmative vote of a majority in voting power of shares of common stock present in person or represented by proxy and entitled to vote thereon. | Abstentions will have the same effect as voting against Proposal 3.”.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Maya Martinez-DavisIndependent · Compensation · Nominations and Corporate Governance Committee · Newly elected | $19,667 | $0 | $207,365 | — | $0 | $227,032 |
| Lori A. WoodsIndependent · Board Chair | 90,000 | 0 | 99,397 | — | 0 | 189,397 |
| Heidi HensonIndependent · Audit (Chair) · Compensation · Nominations and Corporate Governance Committee | 75,000 | 0 | 99,397 | — | 0 | 174,397 |
| Frank Morich, M.D., Ph.DIndependent · Audit · Nominations and Corporate Governance Committee (Chair) | 75,000 | 0 | 99,397 | — | 0 | 174,397 |
| Robert Froman Williamson IIIIndependent · Audit · Compensation (Chair) | 75,000 | 0 | 99,397 | — | 0 | 174,397 |
| Johan (Thijs) SpoorEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $30,000 |
|---|---|
| Annual equity retainer | $99,397 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $334,667 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $334,667 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Perspective Therapeutics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Perspective Therapeutics.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Cogent Biosciences | 2025 | Andrew Robbins | $724,554 | $12,993,250 | $13,447,680 | $561,600 | $27,762,684 |
| 2 | Janux Therapeutics | 2025 | David Campbell | 680,000 | 0 | 12,459,031 | 367,200 | 13,506,231 |
| 3 | CG Oncology | 2025 | Arthur Kuan | 690,000 | 3,451,884 | 7,350,515 | 414,000 | 11,928,401 |
| 4 | Kymera Therapeutics | 2025 | Nello Mainolfi | 693,000 | 0 | 7,318,859 | 519,750 | 8,545,609 |
| 5 | Terns Pharmaceuticals | 2024 | Amy Burroughs | 563,701 | 807,750 | 6,476,968 | 375,000 | 8,240,502 |
| 6 | RAPT Therapeutics | 2024 | Brian Wong | 630,000 | 0 | 5,927,297 | 416,000 | 6,979,539 |
| 7 | Day One Biopharmaceuticals | 2024 | Jeremy Bender | 680,000 | 2,700,280 | 2,664,697 | 501,800 | 6,560,577 |
| 8 | ORIC Pharmaceuticals | 2025 | Jacob Chacko | 657,500 | 826,000 | 3,634,560 | 434,000 | 5,567,164 |
| 9 | Tyra Biosciences | 2025 | Todd Harris | 658,000 | 0 | 4,568,037 | 325,710 | 5,566,997 |
| 10 | Monte Rosa Therapeutics | 2025 | Markus Warmuth | 650,000 | 910,080 | 3,043,648 | 429,000 | 5,032,728 |
| 11 | Relay Therapeutics | 2025 | Sanjiv Patel | 707,846 | 0 | 3,513,900 | 424,708 | 4,646,454 |
| 12 | Y-mAbs Therapeutics | 2024 | Michael Rossi | 705,600 | 1,170,732 | 2,288,662 | 392,596 | 4,557,590 |
| 13 | Aura Biosciences | 2025 | Elisabet de los Pinos | 645,483 | 1,492,378 | 1,513,293 | 284,013 | 3,956,167 |
| 14 | Olema Pharmaceuticals | 2025 | Sean Bohen | 699,920 | 0 | 2,002,000 | 461,900 | 3,178,990 |
| 15 | C4 Therapeutics | 2025 | Andrew Hirsch | 694,925 | 710,730 | 848,007 | 573,313 | 2,940,975 |
| 16 | Tango Therapeutics | 2025 | Barbara Weber | 697,950 | 308,096 | 1,275,328 | 524,250 | 2,823,992 |
| 17 | ALX Oncology | 2025 | Jason Lettmann | 724,500 | 0 | 1,447,488 | 298,856 | 2,470,844 |
| 18 | Perspective Therapeutics | 2025 | Johan Spoor | 680,000 | 0 | 1,302,692 | 408,000 | 2,404,692 |
| 19 | Caribou Biosciences | 2025 | Rachel Haurwitz | 667,534 | 192,818 | 654,541 | 0 | 1,840,965 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Perspective Therapeutics | not disclosed | Options 100 | not disclosed | Aon |
| ALX Oncology | not disclosed | not disclosed | not disclosed | Compensia |
| Aura Biosciences | not disclosed | not disclosed | not disclosed | Pay Governance |
| C4 Therapeutics | 120% | not disclosed | not disclosed | Pearl Meyer |
| Caribou Biosciences | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| CG Oncology | 100% | Options 72 · PSU 28 | No | Pay Governance |
| Cogent Biosciences | 135% | not disclosed | No | Compensia |
| Day One Biopharmaceuticals | 123%% | Stock Options 50 · RSUs 50 | not disclosed | Compensia Inc. |
| Janux Therapeutics | 90% | not disclosed | not disclosed | FW Cook |
| Kymera Therapeutics | 125% | not disclosed | No | Alpine Rewards |
| Monte Rosa Therapeutics | not disclosed | not disclosed | not disclosed | Radford, an Aon Hewitt Company |
| Olema Pharmaceuticals | 110% | Options 100 | not disclosed | Aon |
| ORIC Pharmaceuticals | not disclosed | not disclosed | not disclosed | Aon |
| RAPT Therapeutics | 120% | Option 100 | not disclosed | Aon plc/Radford |
| Relay Therapeutics | 100% | Option 100 | not disclosed | Aon's Human Capital Solutions practice, a division of Aon plc |
| Tango Therapeutics | not disclosed | not disclosed | not disclosed | Pearl Meyer |
| Terns Pharmaceuticals | 120% | not disclosed | No | Alpine Rewards |
| Tyra Biosciences | not disclosed | Options 100 | not disclosed | Aon Rewards Solutions |
| Y-mAbs Therapeutics | 85.6% | not disclosed | No | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Johan Spoor | DEF 14A | 2026-04-16 | 0001193125-26-159005 | Section “Executive Compensation”. As printed: 2,404,692. Filing ↗ |
| 2 | Section 01, Juan Graham | DEF 14A | 2026-04-16 | 0001193125-26-159005 | Section “Summary Compensation Table” · page 27. As printed: 2,234,930. Filing ↗machine: t13 · r11 · c26 · span 642736–642745 |
| 3 | Section 01, Joel Sendek | DEF 14A | 2026-04-16 | 0001193125-26-159005 | Section “Summary Compensation Table” · page 27. As printed: 1,986,552. Filing ↗machine: t13 · r8 · c26 · span 617681–617690 |
| 4 | Section 01, Markus Puhlmann | DEF 14A | 2026-04-16 | 0001193125-26-159005 | Section “Summary Compensation Table” · page 27. As printed: 1,068,083. Filing ↗machine: t13 · r14 · c26 · span 667749–667758 |
| 5 | Section 03, Johan Spoor Option | DEF 14A | 2026-04-16 | 0001193125-26-159005 | Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t13 · r5 · c13 · span 585955–585964 |
| 6 | Section 03, Juan Graham Option | DEF 14A | 2026-04-16 | 0001193125-26-159005 | Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t13 · r11 · c13 · span 638195–638204 |
| 7 | Section 03, Markus Puhlmann Option | DEF 14A | 2026-04-16 | 0001193125-26-159005 | Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t13 · r14 · c13 · span 663205–663212 |
| 8 | Section 03, Joel Sendek Option | DEF 14A | 2026-04-16 | 0001193125-26-159005 | Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t13 · r8 · c13 · span 613137–613146 |
| 9 | Section 07, pay ratio | 10-K | 2026-03-16 | 0000728387-26-000004 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 10 | Section 08, Maya Martinez-Davis | DEF 14A | 2026-04-16 | 0001193125-26-159005 | Section “Director Compensation”. As printed: 227,032. Filing ↗machine: t21 · r7 · c11 · span 1108056–1108265 |
| 11 | Section 08, Lori A. Woods | DEF 14A | 2026-04-16 | 0001193125-26-159005 | Section “Director Compensation”. As printed: 189,397. Filing ↗machine: t21 · r5 · c11 · span 1098860–1099069 |
| 12 | Section 08, Heidi Henson | DEF 14A | 2026-04-16 | 0001193125-26-159005 | Section “Director Compensation”. As printed: 174,397. Filing ↗machine: t21 · r6 · c11 · span 1103454–1103663 |
| 13 | Section 08, Frank Morich, M.D., Ph.D | DEF 14A | 2026-04-16 | 0001193125-26-159005 | Section “Director Compensation”. As printed: 174,397. Filing ↗machine: t21 · r8 · c11 · span 1112663–1112872 |
| 14 | Section 08, Robert Froman Williamson III | DEF 14A | 2026-04-16 | 0001193125-26-159005 | Section “Director Compensation”. As printed: 174,397. Filing ↗machine: r9 · c11 · span 1117274–1117483 |
| 15 | Section 08, Johan (Thijs) Spoor | DEF 14A | 2026-04-16 | 0001193125-26-159005 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 16 | Section 02, Lantheus Alpha Therapy, LLC 2026-08-31 | Form 4 | 2026-09-04 | 0002064832-26-000314 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 17 | Section 02, Lantheus Holdings, Inc. 2026-08-31 | Form 4 | 2026-09-02 | 0002064832-26-000308 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 18 | Section 02, Lantheus Holdings, Inc. 2026-09-01 | Form 4 | 2026-09-03 | 0002064832-26-000310 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Lantheus Alpha Therapy, LLC 2026-09-01 | Form 4 | 2026-09-04 | 0002064832-26-000314 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Lantheus Alpha Therapy, LLC 2026-09-02 | Form 4 | 2026-09-04 | 0002064832-26-000316 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Lantheus Alpha Therapy, LLC 2026-09-03 | Form 4 | 2026-09-08 | 0002064832-26-000318 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Lantheus Alpha Therapy, LLC 2026-09-04 | Form 4 | 2026-09-08 | 0002064832-26-000318 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 06, 2025 vote | Form 8-K | 2025-05-28 | 0000950170-25-078439 | Item 5.07 · say-on-pay result. As reported: 73.68% (votes for as printed: 38,730,185). Filing ↗ |
| 24 | Section 06, 2022 vote | Form 8-K | 2022-12-14 | 0001437749-22-029080 | Item 5.07 · say-on-pay result. As reported: 80.63% (votes for as printed: 53,042,425). Filing ↗ |
| 25 | Section 06, 2019 vote | Form 8-K | 2019-12-13 | 0001437749-19-024428 | Item 5.07 · say-on-pay result. As reported: 51.99% (votes for as printed: 10,152,456). Filing ↗ |
| 26 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 27 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 28 | Section 09b board cost (computed) | Computed | — | — | Cash 334,667 + equity 0 + all other 0 = 334,667, summed across the director compensation table rows.machine: formula: Σ = 334,667 |
| 29 | Cogent Biosciences, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173834 | CEO total compensation as printed in Cogent Biosciences's own proxy. As printed: 27,762,684. Filing ↗machine: r2 · c39 · span 369353–369363 |
| 30 | Janux Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187095 | CEO total compensation as printed in Janux Therapeutics's own proxy. As printed: 13,506,231. Filing ↗machine: r2 · c22 · span 571399–571409 |
| 31 | CG Oncology, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177395 | CEO total compensation as printed in CG Oncology's own proxy. As printed: 11,928,401. Filing ↗machine: r2 · c8 · span 509631–509641 |
| 32 | Kymera Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191495 | CEO total compensation as printed in Kymera Therapeutics's own proxy. As printed: 8,545,609. Filing ↗machine: r2 · c14 · span 676137–676146 |
| 33 | Terns Pharmaceuticals, Section 10b CEO total | DEF 14A | 2025-04-29 | 0000950170-25-060138 | CEO total compensation as printed in Terns Pharmaceuticals's own proxy. As printed: 8,240,502. Filing ↗machine: r3 · c29 · span 385759–385768 |
| 34 | RAPT Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-14 | 0000950170-25-053517 | CEO total compensation as printed in RAPT Therapeutics's own proxy. As printed: 6,979,539. Filing ↗machine: r2 · c23 · span 816852–816861 |
| 35 | Day One Biopharmaceuticals, Section 10b CEO total | DEF 14A | 2025-04-11 | 0001140361-25-013462 | CEO total compensation as printed in Day One Biopharmaceuticals's own proxy. As printed: 6,560,577. Filing ↗machine: r2 · c21 · span 526324–526333 |
| 36 | ORIC Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186911 | CEO total compensation as printed in ORIC Pharmaceuticals's own proxy. As printed: 5,567,164. Filing ↗machine: r2 · c26 · span 435191–435200 |
| 37 | Tyra Biosciences, Section 10b CEO total | DEF 14A | 2026-04-17 | 0001193125-26-160360 | CEO total compensation as printed in Tyra Biosciences's own proxy. As printed: 5,566,997. Filing ↗machine: r2 · c23 · span 216822–216831 |
| 38 | Monte Rosa Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191439 | CEO total compensation as printed in Monte Rosa Therapeutics's own proxy. As printed: 5,032,728. Filing ↗machine: r2 · c25 · span 420815–420824 |
| 39 | Relay Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186929 | CEO total compensation as printed in Relay Therapeutics's own proxy. As printed: 4,646,454. Filing ↗machine: r2 · c29 · span 660153–660162 |
| 40 | Y-mAbs Therapeutics, Section 10b CEO total | DEF 14A | 2025-05-30 | 0001558370-25-008299 | CEO total compensation as printed in Y-mAbs Therapeutics's own proxy. As printed: 4,557,590. Filing ↗machine: r5 · c23 · span 597595–597604 |
| 41 | Aura Biosciences, Section 10b CEO total | DEF 14A | 2026-04-20 | 0001193125-26-163933 | CEO total compensation as printed in Aura Biosciences's own proxy. As printed: 3,956,167. Filing ↗machine: t10 · r2 · c29 · span 480151–480160 |
| 42 | Olema Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191956 | CEO total compensation as printed in Olema Pharmaceuticals's own proxy. As printed: 3,178,990. Filing ↗machine: t29 · r5 · c16 · span 612371–612380 |
| 43 | C4 Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001628280-26-028104 | CEO total compensation as printed in C4 Therapeutics's own proxy. As printed: 2,940,975. Filing ↗machine: span 511808–511817 |
| 44 | Tango Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-17 | 0001193125-26-160287 | CEO total compensation as printed in Tango Therapeutics's own proxy. As printed: 2,823,992. Filing ↗machine: r2 · c39 · span 540371–540380 |
| 45 | ALX Oncology, Section 10b CEO total | DEF 14A | 2026-04-20 | 0001193125-26-163936 | CEO total compensation as printed in ALX Oncology's own proxy. As printed: 2,470,844. Filing ↗machine: r2 · c29 · span 706901–706910 |
| 46 | Perspective Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-16 | 0001193125-26-159005 | CEO total compensation as printed in Perspective Therapeutics's own proxy. As printed: 2,404,692. Filing ↗ |
| 47 | Caribou Biosciences, Section 10b CEO total | DEF 14A | 2026-05-01 | 0001619856-26-000028 | CEO total compensation as printed in Caribou Biosciences's own proxy. As printed: 1,840,965. Filing ↗machine: r2 · c39 · span 191689–191698 |
| 48 | Section 10a, C4 Therapeutics reciprocity | DEF 14A | — | 0001628280-26-028104 | C4 Therapeutics's most recent proxy was read; its disclosed peer group does not include Perspective Therapeutics. Filing ↗ |
| 49 | Section 10a, CG Oncology reciprocity | DEF 14A | — | 0001193125-26-177395 | CG Oncology's most recent proxy was read; its disclosed peer group does not include Perspective Therapeutics. Filing ↗ |
| 50 | Section 10a, Cogent Biosciences reciprocity | DEF 14A | — | 0001193125-26-173834 | Cogent Biosciences's most recent proxy was read; its disclosed peer group does not include Perspective Therapeutics. Filing ↗ |
| 51 | Section 10a, Day One Biopharmaceuticals reciprocity | DEF 14A | — | 0001140361-25-013462 | Day One Biopharmaceuticals's most recent proxy was read; its disclosed peer group does not include Perspective Therapeutics. Filing ↗ |
| 52 | Section 10a, Janux Therapeutics reciprocity | DEF 14A | — | 0001193125-26-187095 | Janux Therapeutics's most recent proxy was read; its disclosed peer group does not include Perspective Therapeutics. Filing ↗ |
| 53 | Section 10a, Relay Therapeutics reciprocity | DEF 14A | — | 0001193125-26-186929 | Relay Therapeutics's most recent proxy was read; its disclosed peer group does not include Perspective Therapeutics. Filing ↗ |
| 54 | Section 10a, Kymera Therapeutics reciprocity | DEF 14A | — | 0001193125-26-191495 | Kymera Therapeutics's most recent proxy was read; its disclosed peer group does not include Perspective Therapeutics. Filing ↗ |
| 55 | Section 10a, Tango Therapeutics reciprocity | DEF 14A | — | 0001193125-26-160287 | Tango Therapeutics's most recent proxy was read; its disclosed peer group does not include Perspective Therapeutics. Filing ↗ |
| 56 | Section 10a, Olema Pharmaceuticals reciprocity | DEF 14A | — | 0001193125-26-191956 | Olema Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Perspective Therapeutics. Filing ↗ |
| 57 | Section 10a, Y-mAbs Therapeutics reciprocity | DEF 14A | — | 0001558370-25-008299 | Y-mAbs Therapeutics's most recent proxy was read; its disclosed peer group does not include Perspective Therapeutics. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.